Safety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions
Authors: Rodriguez-Calienes Aaron , Galecio-Castillo Milagros , Farooqui Mudassir , Hassan Ameer E. , Jumaa Mouhammad A. , Divani Afshin A. , Ribo Marc , Abraham Michael , Petersen Nils H. , Fifi Johanna , Guerrero Waldo R. , Malik Amer M. , Siegler James E. , Nguyen Thanh N. , Yoo Albert J. , Linares Guillermo , Janjua Nazli , Quispe-Orozco Darko , Tekle Wondwossen G. , Alhajala Hisham , Ikram Asad , Rizzo Federica , Qureshi Abid , Begunova Liza , Matsoukas Stavros , Vigilante Nicholas , Salazar-Marioni Sergio , Abdalkader Mohamad , Gordon Weston , Soomro Jazba , Turabova Charoskon , Vivanco-Suarez Juan , Mokin Maxim , Yavagal Dileep R. , Jovin Tudor , Sheth Sunil , Ortega-Gutierrez Santiago 
Published: August 2023

BACKGROUND:
We aimed to describe the safety and efficacy of mechanical thrombectomy (MT) with or without intravenous thrombolysis (IVT) for patients with tandem lesions and whether using intraprocedural antiplatelet therapy influences MT’s safety with IVT treatment.

METHODS:
This is a subanalysis of a pooled, multicenter cohort of patients with acute anterior circulation tandem lesions treated with MT from 16 stroke centers between January 2015 and December 2020. Primary outcomes included symptomatic intracranial hemorrhage (sICH) and parenchymal hematoma type 2. Additional outcomes included hemorrhagic transformation, successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3), complete reperfusion (modified Thrombolysis in Cerebral Infarction score 3), favorable functional outcome (90-day modified Rankin Scale score 0–2), excellent functional outcome (90-day modified Rankin Scale score 0–1), in-hospital mortality, and 90-day mortality.

RESULTS:

Of 691 patients, 512 were included (218 underwent IVT+MT and 294 MT alone). There was no difference in the risk of sICH (adjusted odds ratio [aOR], 1.22 [95% CI, 0.60–2.51];
P
=0.583), parenchymal hematoma type 2 (aOR, 0.99 [95% CI, 0.47–2.08];
P
=0.985), and hemorrhagic transformation (aOR, 0.95 [95% CI, 0.62–1.46];
P
=0.817) between the IVT+MT and MT alone groups after adjusting for confounders. Administration of IVT was associated with an increased risk of sICH in patients who received intravenous antiplatelet therapy (aOR, 3.04 [95% CI, 0.99–9.37];
P
=0.05). The IVT+MT group had higher odds of a 90-day modified Rankin Scale score 0 to 2 (aOR, 1.72 [95% CI, 1.01–2.91];
P
=0.04). The odds of successful reperfusion, complete reperfusion, 90-day modified Rankin Scale score 0 to 1, in-hospital mortality, or 90-day mortality did not differ between the IVT+MT versus MT alone groups.

CONCLUSIONS:
Our study showed that the combination of IVT with MT for tandem lesions did not increase the overall risk of sICH, parenchymal hematoma type 2, or overall hemorrhagic transformation independently of the cervical revascularization technique used. However, intraprocedural intravenous antiplatelet therapy during acute stent implantation might be associated with an increased risk of sICH in patients who received IVT before MT. Importantly, IVT+MT treatment was associated with a higher rate of favorable functional outcomes at 90 days.